Estrella shares surge 10.70% premarket as STARLIGHT-1 trial advances to Phase II with strong safety and efficacy data.

Estrella Immunopharma (NASDAQ: ESLA) surged 10.70% in premarket trading after announcing that its EB103 CD19-redirected ARTEMIS® T-cell therapy advanced to Phase II of the STARLIGHT-1 trial following a favorable safety review. An independent Data Safety Monitoring Board confirmed no treatment-related serious adverse events in nine patients, including high-risk individuals ineligible for existing CD19 therapies, and highlighted a 100% complete response rate in the high-dose cohort. The milestone underscores EB103’s potential as a best-in-class therapy with broader applicability to relapsed/refractory B-cell NHL patients, including high-risk subgroups. The Phase II expansion will evaluate safety and efficacy at the recommended dose, with data expected to inform pivotal trial strategies. The news directly relates to the company’s core clinical-stage biopharmaceutical development and positions EB103 as a differentiated candidate in the CAR-T space.